Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) on Monday, soared 15.79% from the previous trading day, before settling in for the closing price of $1.14. Within the past 52 weeks, CYCC’s price has moved between $0.75 and $11.34.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -20.00% annually for the last half of the decade. The company achieved an average annual earnings per share of 88.30%. With a float of $2.05 million, this company’s outstanding shares have now reached $2.15 million.
In terms of profitability, gross margin is 76.25%, operating margin of -30398.75%, and the pretax margin is -30595.0%.
Cyclacel Pharmaceuticals Inc (CYCC) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Cyclacel Pharmaceuticals Inc is 4.50%, while institutional ownership is 10.66%. The most recent insider transaction that took place on Dec 21 ’23, was worth 6,252. In this transaction an insider of this company bought 1,886 shares at a rate of $3.31, taking the stock ownership to the 33,378 shares. Before that another transaction happened on Dec 21 ’23, when Company’s President and CEO bought 6,070 for $3.31, making the entire transaction worth $20,122. This insider now owns 68,658 shares in total.
Cyclacel Pharmaceuticals Inc (CYCC) Latest Financial update
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -7.35 earnings per share (EPS) for the period falling under the consensus outlook (set at -5.45) by -1.9. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.4 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 88.30% per share during the next fiscal year.
Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) Trading Performance Indicators
Cyclacel Pharmaceuticals Inc (CYCC) is currently performing well based on its current performance indicators. A quick ratio of 1.07 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 35.48.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -17.52, a number that is poised to hit -0.56 in the next quarter and is forecasted to reach -1.99 in one year’s time.
Technical Analysis of Cyclacel Pharmaceuticals Inc (CYCC)
Let’s dig in a bit further. During the last 5-days, its volume was 3.62 million. That was better than the volume of 0.43 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 45.50%. Additionally, its Average True Range was 0.17.
During the past 100 days, Cyclacel Pharmaceuticals Inc’s (CYCC) raw stochastic average was set at 24.43%, which indicates a significant decrease from 45.97% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 121.24% in the past 14 days, which was higher than the 96.87% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.0632, while its 200-day Moving Average is $1.8413. However, in the short run, Cyclacel Pharmaceuticals Inc’s stock first resistance to watch stands at $1.4367. Second resistance stands at $1.5533. The third major resistance level sits at $1.6667. If the price goes on to break the first support level at $1.2067, it is likely to go to the next support level at $1.0933. The third support level lies at $0.9767 if the price breaches the second support level.
Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) Key Stats
Market capitalization of the company is 2.84 million based on 1,463K outstanding shares. Right now, sales total 420 K and income totals -22,560 K. The company made 30 K in profit during its latest quarter, and -2,950 K in sales during its previous quarter.
